Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TGFBR1 | P36897 | 4/20 | 0.51 |
| ▸ | JAK2 | O60674 | 2/20 | 0.49 |
| ▸ | NTRK1 | P04629 | 1/20 | 0.49 |
| ▸ | JAK1 | P23458 | 1/20 | 0.49 |
| ▸ | TYK2 | P29597 | 1/20 | 0.49 |
| ▸ | JAK3 | P52333 | 1/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.46 |
| ▸ | IRAK4 | Q9NWZ3 | 9/20 | 0.46 |
| ▸ | TAS2R14 | Q9NYV8 | 1/20 | 0.46 |
| ▸ | PIM1 | P11309 | 1/20 | 0.43 |
| ▸ | PIM3 | Q86V86 | 1/20 | 0.43 |
| ▸ | PIM2 | Q9P1W9 | 1/20 | 0.43 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.42 |
| ▸ | NPC1 | O15118 | 1/20 | 0.41 |
| ▸ | RAB9A | P51151 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL405830 | 0.88 | JAK2 (0.54) | TGFBR1JAK2JAK1TYK2JAK3 | |
| SCHEMBL402160 | 0.85 | JAK2 (0.51) | TGFBR1JAK2JAK1TYK2JAK3 | |
| SCHEMBL405943 | 0.85 | HTT (0.56) | TGFBR1JAK2NTRK1JAK1TYK2 | |
| SCHEMBL400999 | 0.84 | TAS2R14 (0.60) | TGFBR1JAK2NTRK1JAK1TYK2 | |
| SCHEMBL402252 | 0.83 | JAK2 (0.58) | TGFBR1JAK2JAK1TYK2JAK3 | |
| SCHEMBL402374 | 0.83 | TGFBR1 (0.49) | TGFBR1JAK2NTRK1JAK1TYK2 | |
| SCHEMBL405540 | 0.82 | JAK2 (0.50) | TGFBR1JAK2NTRK1JAK1TYK2 | |
| SCHEMBL404687 | 0.81 | HTT (0.53) | JAK2NTRK1JAK1TYK2JAK3 | |
| SCHEMBL406630 | 0.81 | JAK2 (0.54) | TGFBR1JAK2JAK1TYK2JAK3 | |
| SCHEMBL405541 | 0.80 | JAK2 (0.49) | TGFBR1JAK2NTRK1JAK1TYK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120022043-A1 | PYRAZOLOPYRIMIDINE JAK INHIBITOR COMPOUNDS AND METHODS | GENENTECH, INC. (US) | 2012-01-26 | — | — | US | disclosed |
| US-20120022043-A1 | PYRAZOLOPYRIMIDINE JAK INHIBITOR COMPOUNDS AND METHODS | GENENTECH, INC. (US) | 2012-01-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120022043-A1 | PYRAZOLOPYRIMIDINE JAK INHIBITOR COMPOUNDS AND METHODS | JAK2, JAK1, JAK3 | TGFBR1 1184/4885JAK2 1/4885NTRK1 2693/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.